Penumbra, Inc.

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:01 2023-12-08 pm EST			5-day change	1st Jan Change
224.04 ^USD	+0.38%		-1.63%	+0.71%

Nov. 28	Transcript : Penumbra, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 01:30 PM	CI
Nov. 28	Penumbra, Inc. Announces First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash for Treatment of Acute Pulmonary Embolism	CI

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Penumbra, Inc.

Transcript : Penumbra, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 01:30 PM	Nov. 28	CI
Penumbra, Inc. Announces First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash for Treatment of Acute Pulmonary Embolism	Nov. 28	CI
Medical device stocks rise in relief after Wegovy heart benefits data	Nov. 13	RE
Medical device makers rise on relief after Wegovy obesity trial data	Nov. 13	RE
Deutsche Bank Cuts Penumbra Price Target to $257 From $367, Maintains Buy Rating	Nov. 03	MT
Morgan Stanley Cuts Price Target on Penumbra to $240 From $265, Maintains Equalweight Rating	Nov. 03	MT
Sector Update: Health Care Stocks Gain Premarket Friday	Nov. 03	MT
Penumbra's Q3 Non-GAAP Earnings, Revenue Rise	Nov. 03	MT
Penumbra, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (PEN) PENUMBRA Posts Q3 Revenue $270.9M, vs. Street Est of $265.1M	Nov. 02	MT
Earnings Flash (PEN) PENUMBRA Reports Q3 EPS $0.67, vs. Street Est of $0.45	Nov. 02	MT
Transcript : Penumbra, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02	CI
Penumbra, Inc. Provides Earnings Guidance for the Full Year 2023	Nov. 02	CI
Penumbra, Inc. Announces Latest STRIKE-PE Data Evaluating Penumbra's Indigo Aspiration System with Lightning	Nov. 01	CI
Penumbra Insider Sold Shares Worth $2,086,417, According to a Recent SEC Filing	Oct. 16	MT
Penumbra Insider Sold Shares Worth $142,691, According to a Recent SEC Filing	Oct. 05	MT
Citigroup Cuts Price Target on Penumbra to $320 From $390, Maintains Buy Rating	Oct. 02	MT
Penumbra Insider Sold Shares Worth $2,887,821, According to a Recent SEC Filing	Sep. 14	MT
Transcript : Penumbra, Inc. Presents at Baird's Global Healthcare Conference 2023, Sep-12-2023 02:00 PM	Sep. 12	CI
Transcript : Penumbra, Inc. Presents at Wells Fargo Securities Healthcare Conference 2023, Sep-06-2023 08:00 AM	Sep. 06	CI
Morgan Stanley Initiates Coverage on Penumbra With Equal Weight Rating, $265 Price Target	Sep. 06	MT
Insider Sell: Penumbra	Aug. 15	MT
Transcript : Penumbra, Inc. Presents at Canaccord Genuity 43rd Annual Growth Conference, Aug-09-2023 09:00 AM	Aug. 09	CI
Wells Fargo Adjusts Price Target on Penumbra to $337 From $320, Maintains Overweight Rating	Aug. 02	MT
Penumbra's Q2 Non-GAAP EPS, Revenue Gain; Full Year Revenue Outlook Lifted	Aug. 01	MT

Penumbra, Inc. is a global healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. It has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The Company's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The Company sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-02-26 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Penumbra, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

224.04USD

Average target price

258.62USD

Spread / Average Target

+15.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
PENUMBRA, INC.	+0.71%	8 647 M $
GETINGE AB	+7.26%	6 029 M $
MASIMO CORPORATION	-29.46%	5 515 M $
ASAHI INTECC CO., LTD.	+30.18%	5 276 M $
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+4.74%	4 610 M $
INARI MEDICAL, INC.	-0.80%	3 631 M $
APT MEDICAL INC.	+24.56%	3 551 M $
ANDON HEALTH CO., LTD.	-27.31%	2 423 M $
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD	-21.29%	2 294 M $
SKAN GROUP AG	+26.98%	2 042 M $